Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis

Prior treatment

• Systemic treatment for unresectable or metastatic disease for more than three months prior to enrollment
• Any evidence of extensive retroperitoneal lymph node metastases not amenable to resection during gastrectomy
• Uncontrolled intercurrent illness including, but not limited to, the following conditions:
  • Ongoing or active infection
  • Symptomatic congestive heart failure
  • Stroke (including transient ischemic attack \[TIA\]), myocardial infarction (MI), or other ischemic event,) within 3 months before initiation of treatment
  • Unstable angina pectoris
  • Cardiac arrhythmia
• History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ and not treated with systemic therapy.
• Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• Prior surgery that would preclude safe diagnostic laparoscopy and port placement

Other illness

• Any evidence of small or large bowel obstruction with the exception of gastric outlet obstruction due to primary malignancy
• Has an active infection requiring systemic therapy.
• Has a known history of active tuberculosis (TB; Bacillus tuberculosis).

Lab values

• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator

Other

• Any evidence of distant, solid organ metastases (visceral (liver, lung, brain), bone, extra-abdominal)
• Inability to comply with study and follow-up procedures as judged by the Investigator

• Patients must have histologically or cytologically confirmed primary gastric or gastroesophageal adenocarcinoma and have received a minimum of three months of first line systemic treatment without visceral metastatic progression
• Must have peritoneal cytology positive disease or peritoneal carcinomatosis detected by imaging, laparoscopy or laparotomy
• Age ≥ 18 -75 years
• Performance status: ECOG performance status ≤ 2 (Appendix A) . ECOG 2 allowed is attributed to malignancy (rather than comorbidities)
• Life expectancy of greater than 6 months
• Adequate organ and marrow function as defined below:
  • Leukocytes: ≥ 2,000/mcL
  • Absolute Neutrophil Count: ≥ 1,500/mcL
  • Platelets: ≥ 80,000/mcL
  • Total Bilirubin: within normal institutional limits
  • AST(SGOT)/ALT(SPGT): ≤5 X institutional upper limit of normal
  • Creatinine: \< 1.5 X institutional upper limit of normal
  • Hemoglobin: \> 8.0 g/dL (may be transfused)
  • Serum albumin: ≥ g/dL
• Ability to understand and the willingness to sign a written informed consent